Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.
Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, ...
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...
Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...
Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...
BofA lowered the firm’s price target on Merck (MRK) to $112 from $118 and keeps a Buy rating on the shares. Q4 results were “decent,” but 2025 ...
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
Palantir stock surges as artificial-intelligence gains drive an earnings and revenue beat, China begins an antitrust probe ...
Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback